BI 836845

· Boehringer Ingelheim

Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for BI 836845, covering 2025-06-19 to 2025-07-25. Get the full timeline:

Most recent: Clinical Trial Update: Phase I Trial of BI 836845 for Various Solid Cancer [Phase 1]